Stockreport

NLS Initiates Phase 2 Trial for Quilience in Narcolepsy and Announces First Patient Enrolled

NLS Pharmaceutics Ltd. - Common Shares  (NLSP) 
PDF STANS, SWITZERLAND / ACCESSWIRE / September 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical [Read more]